Skip to main content

Table 1 Age and gender distribution of selected patients

From: Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

  

anti-CTLA-4

anti-PD-1

  

responders

non-responders

responders

non-responders

Age

< 30

0

1

0

0

30–39

0

1

2

0

40–49

1

4

2

2

50–59

3

0

6

6

60–69

4

5

4

6

> 70

2

3

7

5

Ave. age (years)

62.3

56.4

61.3

61.4

STDEV (years)

10.9

17.7

15.3

11.6

p value (U test)

0.35

0.81

Gender

Female

4

4

8

7

Male

6

10

13

12

Clinical response

CR

0

 

2

 

PR

2

 

12 (3 borderline CR)

 

SD

8

 

7

 

PD

 

14

 

19

  1. Age and gender distribution of patients in the anti-CTLA-4 and anti-PD-1 cohorts in relation to clinical response are shown. More details regarding patient sample selection can be found in the Materials and Methods section. p values shown are from U test between responders and non-responders. p < 0.05 was considered statistically significant
Back to article page